2023 - Research.com Best Scientist Award
2022 - Research.com Best Scientist Award
2020 - Member of the National Academy of Sciences
2014 - Fellow of the American Academy of Arts and Sciences
2014 - Fellow, National Academy of Inventors
2009 - Member of the National Academy of Medicine (NAM)
2009 - Paul Marks Prize for Cancer Research, Memorial Sloan Kettering Cancer Center
Member of the Association of American Physicians
In his works, Arul M. Chinnaiyan undertakes multidisciplinary study on Cancer research and Oncology. Arul M. Chinnaiyan performs integrative Oncology and Cancer research research in his work. In his papers, Arul M. Chinnaiyan integrates diverse fields, such as Cancer and Adenocarcinoma. His Adenocarcinoma study frequently involves adjacent topics like Genetics. His KRAS research extends to Genetics, which is thematically connected. Arul M. Chinnaiyan integrates several fields in his works, including KRAS and Cancer. His work blends Gene and Transfection studies together. His Small interfering RNA research extends to the thematically linked field of Transfection. Small interfering RNA is closely attributed to Cell culture in his work.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
S.A. Tomlins;D.R. Rhodes;S. Perner;S.M. Dhanasekaran.
Science (2005)
FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex.
Marta Muzio;Arul M. Chinnaiyan;Frank C. Kischkel;Karen O'Rourke.
Cell (1996)
ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform
Daniel R. Rhodes;Jianjun Yu;K. Shanker;Nandan Deshpande.
Neoplasia (2004)
FADD, a novel death domain-containing protein, interacts with the death domain of fas and initiates apoptosis
Arul M. Chinnaiyan;Karen O'Rourke;Muneesh Tewari;Vishva M. Dixit.
Cell (1995)
The polycomb group protein EZH2 is involved in progression of prostate cancer
Sooryanarayana Varambally;Saravana M. Dhanasekaran;Ming Zhou;Terrence R. Barrette.
Nature (2002)
Integrative clinical genomics of advanced prostate cancer
Dan Robinson;Eliezer M. Van Allen;Eliezer M. Van Allen;Yi Mi Wu;Nikolaus Schultz.
Cell (2015)
Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control
Bin Zhao;Xiaomu Wei;Weiquan Li;Ryan S. Udan;Ryan S. Udan.
Genes & Development (2007)
The mutational landscape of lethal castration-resistant prostate cancer
Catherine S. Grasso;Yi Mi Wu;Dan R. Robinson;Xuhong Cao.
Nature (2012)
The receptor for the cytotoxic ligand TRAIL
Guohua Pan;Karen O'Rourke;Arul M. Chinnaiyan;Reiner Gentz.
Science (1997)
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression
Arun Sreekumar;Laila M. Poisson;Thekkelnaycke M. Rajendiran;Amjad P. Khan.
Nature (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Michigan–Ann Arbor
University of Michigan–Ann Arbor
University of Bern
University of Michigan–Ann Arbor
Johns Hopkins University School of Medicine
University of Colorado Anschutz Medical Campus
University of Trento
University of Sydney
Northwestern University
University of Michigan–Ann Arbor
Rutgers, The State University of New Jersey
Korea Institute of Science and Technology
Jiangsu University of Science and Technology
Washington University in St. Louis
University of Minnesota
University of Missouri
University of Montpellier
Australian National University
University of Göttingen
Wageningen University & Research
Scottish Association For Marine Science
Loyola University Chicago
Oregon Health & Science University
Seoul National University Hospital
Mayo Clinic
Mayo Clinic